

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT MW RECEIVED

In re Application of: Jinhua Xiang, et al.

Serial No.: 09/828,498

Filed: April 5, 2001

For: FULL-LENGTH GB VIRUS C (HEPATITIS G VIRUS) RNA

TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV

Group Art Unit: 1645

TECH CENTER 1600/2900

Examiner: Unknown

Atty. Dkt. No.: IOWA:030US/GNS

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

August 30, 2001

Date

Gina Shishima

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10008943/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Gina N. Shishima Reg. No. 45,104

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

August 30, 2001



WRITER'S INTERNET ADDRESS: GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER: 512/536-3081

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701 SEP 0 5 2001

TECH CENTER 1600/2900

MASHINGTON D.C AUSTIN SAN ANTONIO DALLAS NEW YORK LOS ANGELES MINNEAPOLIS LONDON HONG KONG

August 30, 2001

FILE: IOWA:030US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

August 30, 2001

Date

Gina Shishima

Commissioner for Patents Washington, DC 20231

RE:

SN 09/828,498 "FULL-LENGTH GB VIRUS C (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV" – Jinhua Xiang, et al. (Client Reference: UIRF No. MO-46)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A4, C1-C59).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10008943/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima Reg. No. 45,104

GNS/cmb

Encl: as noted

25068530.1